Please login to the form below

Benicar

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Benicar was produced by Daiichi Sankyo.

Daiichi Sankyo to shut down German antibody unit U3

The restricting comes as Daiichi Sankyo faces the loss of patent protection in the US for Benicar (olmesartan), a $2.4bn-a-year product used to treat high blood pressure.

Daiichi Sankyo cuts a swathe through US workforce

Japan's Daiichi Sankyo is planning to the slash the size of its US workforce as it contends with the loss of patent protection for top-selling drug Benicar. ... The company will need late-stage pipeline candidates to deliver if it is to ride out the

Daiichi Sankyo pays $39m in whistleblower case

several of its products, including high blood pressure treatment Benicar (olmesartan) and various combinations of the drug with other antihypertensive agents.

Takeda launches Azilva for blood pressure in Japan

Daiichi Sankyo's Benicar/Olmetec (olmesartan).

Result pages: 1 | 2 | 3 | 4 (Next 4)

Data provided by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology

Featured jobs

Editorial Director – Medical Education – Oxford: Negotiable

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Medical Writer - (London, Brighton or Copenhagen): Competitive

Senior Account Manager or AD - Medical Communications: Salary TBC

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Account Manager – Med Comms – London: Salary TBC

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Senior Programme Executive: Salary TBC

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Scientific Director: Great salary and bebefits

Senior Medical Writer: Great salary and bebefits

Senior Account Manager – Med Comms – Kent: Salary TBC

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Senior Account Manager / Account Director: Great salary and bebefits

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Editor – Medical Education Agency – Bucks: Salary TBC

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Senior Medical Writer: Great salary and benefits

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...